AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

AbbVie's office in South San Francisco, California

Cancer

AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B

The deal, which involves a $700 million upfront payment, gives AbbVie access to ISB 2001, a clinical-stage first-in-class trispecific antibody currently being tested for certain kinds of multiple myeloma as well as autoimmune indications.

July 10, 2025

1 min read

Dan Samorodnitsky

Podcast

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health Secretary Robert F. Kennedy Jr. and a plea from patients with ALS for access to BrainStorm’s NurOwn.

July 9, 2025

1 min read

Heather McKenzie

Podcast

CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA removes CAR T guardrails; AbbVie snaps up Capstan for $1.2B to end first half; and psychedelics take off again with data from Compass and Beckley.

July 2, 2025

1 min read

Heather McKenzie

Contemporary art collage, female palms in the orange circle, a bag of money. Concept of business and finance.

Mergers & acquisitions

AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies

The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’ in vivo edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.

June 30, 2025

2 min read

Dan Samorodnitsky

Approvals

Moderna, Merck, UroGen, Score RSV and Cancer Nods in June

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an approval in bladder cancer, and more key regulatory nods from the past month.

June 30, 2025

9 min read

Tristan Manalac

vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake

Cancer

Roche, AbbVie’s Venclexta Stumbles Again, This Time in Myelodysplastic Syndromes

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic syndromes.

June 17, 2025

1 min read

Tristan Manalac

Hiring collage showing HR checking applicant information

Job Trends

Hiring Outlook: Indiana, California Top 2 Hot Spots for Jobs in May

The biopharma job market failed to turn around in May, but employers were still hiring, especially in Indiana and California, based on BioSpace data. The two states had the most job postings live on BioSpace last month, with Indiana showing a 108% year-over-year increase.

June 12, 2025

4 min read

Angela Gabriel

Holds tickets in hand, isolated on white background. Vector flat. stock illustration

Deals

Biopharma Right of First Negotiation Not a Golden Ticket to M&A, Jefferies Finds

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow through with M&A after earning a right of first negotiation. Sanofi, on the other hand, almost always does, as it did with Vigil recently.

June 11, 2025

6 min read

Annalee Armstrong